Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15817 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Abderrahim Oulhaj und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Epidemiology, College of Medicine and Health Sciences, Khalifa University of Sciences and Technology, Abu Dhabi, Unit…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Heart Failure, Hospitalization. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amylin Pharmaceuticals Inc, wholly-owned subsidiary of AstraZeneca.
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
Aim
The decline in estimated glomerular filtration rate (eGFR), a significant predictor of cardiovascular disease (CVD), occurs heterogeneously in people with diabetes because of various risk factors. We investigated the role of eGFR decline in predicting CVD events in people with type 2 diabetes in both primary and secondary CVD prevention settings. Materials and Methods Bayesian joint modelling of repeated measures of eGFR and time to CVD event was applied to the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial to examine the association between the eGFR slope and the incidence of major adverse CV event/hospitalization for heart failure (MACE/hHF) (non‐fatal myocardial infarction, non‐fatal stroke, CV death, or hospitalization for heart failure). The analysis was adjusted for age, sex, smoking, systolic blood pressure, baseline eGFR, antihypertensive and lipid‐lowering medication, diabetes duration, atrial fibrillation, high‐density cholesterol, total cholesterol, HbA1c and treatment allocation (once‐weekly exenatide or placebo).
Results
Data from 11 101 trial participants with ( n = 7942) and without ( n = 3159) previous history of CVD were analysed. The mean ± SD eGFR slope per year in participants without and with previous CVD was −0.68 ± 1.67 and −1.03 ± 2.13 mL/min/1.73 m 2 , respectively. The 5‐year MACE/hHF incidences were 7.5% (95% CI 6.2, 8.8) and 20% (95% CI 19, 22), respectively. The 1‐SD decrease in the eGFR slope was associated with increased MACE/hHF risks of 48% (HR 1.48, 95% CI 1.12, 1.98, p = 0.007) and 33% (HR 1.33, 95% CI 1.18,1.51, p < 0.001) in participants without and with previous CVD, respectively. Conclusions eGFR trajectories over time significantly predict incident MACE/hHF events in people with type 2 diabetes with and without existing CVD, with a higher hazard ratio for MACE/hHF in the latter group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health and Epidemiology, College of Medicine and Health Sciences, Khalifa University of Sciences and Technology, Abu Dhabi, United Arab Emirates.
- Biotechnology Center, Khalifa University of Sciences and Technology, Abu Dhabi, United Arab Emirates.
- Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
- Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
- Division of Nephrology, Medical University of Graz, Graz, Austria.
- Mathematics and Statistics Department, Zayed University, Abu Dhabi, United Arab Emirates.
ORCID-Profile: Faisal Aziz, Ruth L Coleman, Harald Sourij
Förderung
- Amylin Pharmaceuticals Inc
- wholly-owned subsidiary of AstraZeneca
Zitieren
APA
Oulhaj, A., Aziz, F., Suliman, A., Eller, K., Bentoumi, R., Buse, J. B., Al Mahmeed, W., von Lewinski, D., Coleman, R. L., Holman, R. R., & Sourij, H. (2024). Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15817
Vancouver
Oulhaj A, Aziz F, Suliman A, Eller K, Bentoumi R, Buse JB, et al. Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15817
BibTeX
@article{Oulhaj2024,
author = {Oulhaj, Abderrahim and Aziz, Faisal and Suliman, Abubaker and Eller, Kathrin and Bentoumi, Rachid and Buse, John B and Al Mahmeed, Wael and von Lewinski, Dirk and Coleman, Ruth L and Holman, Rury R and Sourij, Harald},
title = {Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15817}
}
EUVIMED